Clinical Trial

Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer

Study acronym: FREEDOM
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this study is to evaluate the efficacy and safety of oral paclitaxel solution plus fruquintinib as second-line therapy in adult subjects with advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-02
Trial Details
NCT Number NCT07552402
Lead Sponsor Harbin Medical University
Conditions Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Enrollment 150 participants
Start Date 2026-06-10
Primary Completion 2027-12-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-01